Abstract:Qing-Liang Fang, 1, * Kai-Chun Li, 2, * Lei Wang, 1 Xiang-Lian Gu, 1 Ren-Jie Song, 1 Song Lu 1 1 Department of Radiation Oncology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Department of Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai, People's Republic of China *These authors contributed equally to this work Correspondence: Qing-Liang Fang Department of Radiation Oncology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China Tel +8621-64385700 Email yuxun9582581581@163.com Objective: This study set out to explore the regulatory mechanism of miR-130a-5p in cisplatin (DDP)-resistant gastric cancer (GC) cells. Materials and Methods: Forty cases of GC and paracancerous tissues were collected, and the miR-130a-5p and CCL22 levels were detected by qRT-PCR. DDP-resistant cell lines of GC cells were established. Cell viability, invasion, and apoptosis were measured by CCK-8, Transwell, and flow cytometry, respectively. The relationship between miR-130a-5p and CCL22 was verified by dual-luciferase reporter enzyme, and the protein levels of caspase-3, bax, bcl-2, and CCL22 were determined by Western blot. Results: miR-130a-5p was low expressed in GC tissues and cells, while CCL22 showed marked negative correlation, and the area under the curve (AUC) for diagnosing GC was not less than 0.850. Up-regulating miR-130a-5p or knocking down CCL22 expression can inhibit the proliferation and invasion of GC cells and promote their apoptosis, reverse the resistance of NCI-N87/DDP to DDP, and also enhance the chemosensitivity of GC cells. Dual-luciferase reporter enzyme identified that there was a targeted relationship between miR-130a-5p and CCL22. At the same time, miR-130a-5p and CCL22 were up-regulated or down-regulated, and the malignant proliferation, invasion, apoptosis, and DDP chemotherapy resistance of the cells had no difference compared with miR-NC with transfection-unrelated sequences. Conclusion: Up-regulating miR-130a-5p can enhance the sensitivity of DDP-resistant GC cells to chemotherapy and regulate their biological function by targeted inhibition of CCL22. Keywords: miR-130a-5p, CCL22, cisplatin, gastric cancer, chemosensitivity

MicroRNA‐130b Targets PTEN to Induce Resistance to Cisplatin in Lung Cancer Cells by Activating Wnt/β‐catenin Pathway

MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway

Regulatory Effects and Associated Mechanisms of Mir-130A Molecules on Cisplatin Resistance in Ovarian Cancer A2780 Cell Lines

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells

Upregulated Mir-130A Increases Drug Resistance by Regulating RUNX3 and Wnt Signaling in Cisplatin-Treated HCC Cell

MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

Mir-135A/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

MiR-130 Exerts Tumor Suppressive Function on the Tumorigenesis of Human Non-Small Cell Lung Cancer by Targeting PTEN.

Mir-133B Reverses Cisplatin Resistance by Targeting GSTP1 in Cisplatin-Resistant Lung Cancer Cells.

Targeted Inhibition of CCL22 by miR-130a-5p Can Enhance the Sensitivity of Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy

MiR-5100 Increases the Cisplatin Resistance of the Lung Cancer Stem Cells by Inhibiting the Rab6

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis

miR-140-3p enhances cisplatin sensitivity and attenuates stem cell-like properties through repressing Wnt/β-catenin signaling in lung adenocarcinoma cells

miR-185-5p May Modulate the Chemosensitivity of LUSC to Cisplatin via Targeting PCDHA11: Multi-omics Analysis and Experimental Validation

[Expression of Mir-130A in Cisplatin Resistant Cell Lines of Ovarian Cancer].

Negative Regulation of PTEN by MicroRNA-221 and Its Association with Drug Resistance and Cellular Senescence in Lung Cancer Cells

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer